Cargando…

The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models

In the present study, we investigated the activity of XL388, a novel mammalian target of rapamycin (mTOR) complex 1/2 (mTORC1/2) dual inhibitor, in preclinical osteosarcoma (OS) models. XL388 was cytotoxic, cytostatic and pro-apoptotic to multiple established OS cell lines and primary human OS cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yun-Rong, Zhou, Xiao-zhong, Zhu, Lun-qing, Yao, Chen, Fang, Jian-Feng, Zhou, Feng, Deng, Xiong-Wei, Zhang, Yun-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226526/ https://www.ncbi.nlm.nih.gov/pubmed/27385099 http://dx.doi.org/10.18632/oncotarget.10389

Ejemplares similares

The therapeutic value of XL388 in human glioma cells
por: Zhong, Shan, et al.
Publicado: (2020)

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent
por: Xiong, Zuquan, et al.
Publicado: (2017)

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models
por: Zhang, Hao, et al.
Publicado: (2013)

mTORC1 Maintains the Tumorigenicity of SSEA-4(+) High-Grade Osteosarcoma
por: Zhang, Wu, et al.
Publicado: (2015)

The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent
por: Li, Chen, et al.
Publicado: (2015)

Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
por: Qian, Jianchang, et al.
Publicado: (2016)

Author Correction: mTORC1 Maintains the Tumorigenicity of SSEA-4 (+) High-Grade Osteosarcoma
por: Zhang, Wu, et al.
Publicado: (2021)

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension
por: Tang, Haiyang, et al.
Publicado: (2018)

mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)

Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T‐cell leukemia
por: Kawata, Takahito, et al.
Publicado: (2017)

Differential controls of MAIT cell effector polarization by mTORC1/mTORC2 via integrating cytokine and costimulatory signals
por: Tao, Huishan, et al.
Publicado: (2021)

mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors
por: Zhu, Ping Jun, et al.
Publicado: (2018)

Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry
por: Rogers-Broadway, Karly-Rai, et al.
Publicado: (2019)

Dual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
por: Tasneen, Rokeya, et al.
Publicado: (2021)

Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
por: Chen, Long, et al.
Publicado: (2015)

The metabolic waste ammonium regulates mTORC2 and mTORC1 signaling
por: Merhi, Ahmad, et al.
Publicado: (2017)

Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC)
por: Zhang, Yu, et al.
Publicado: (2018)

Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis
por: Ren, Qian‐Nan, et al.
Publicado: (2021)

mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation
por: Ding, Xiaolei, et al.
Publicado: (2016)

LPS Induces mTORC1 and mTORC2 Activation During Monocyte Adhesion
por: Ribeiro, Marcelle C., et al.
Publicado: (2018)

mTORC1 and mTORC2 differentially promote natural killer cell development
por: Yang, Chao, et al.
Publicado: (2018)

mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV
por: Yang, Jin Young, et al.
Publicado: (2019)

Dopamine neuron morphology and output are differentially controlled by mTORC1 and mTORC2
por: Kosillo, Polina, et al.
Publicado: (2022)

Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells
por: Zhen, Yun-fang, et al.
Publicado: (2016)

In Situ Analysis of mTORC1/C2 and Metabolism-Related Proteins in Pediatric Osteosarcoma
por: Mohás, Anna, et al.
Publicado: (2022)

Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma
por: Wang, Quan, et al.
Publicado: (2013)

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
por: Feldman, Morris E, et al.
Publicado: (2009)

LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control
por: Gan, Wenjian, et al.
Publicado: (2020)

Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion
por: Kauffman, Eric C., et al.
Publicado: (2019)

Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer
por: Mirkheshti, Nooshin, et al.
Publicado: (2016)

Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2
por: Luo, Yan, et al.
Publicado: (2015)

Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function
por: Wang, Fangjie, et al.
Publicado: (2018)

Regulation of Autophagy through TORC1 and mTORC1
por: Noda, Takeshi
Publicado: (2017)

Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect
por: Sousa-Victor, Pedro, et al.
Publicado: (2015)

Therapeutic potential of a dual mTORC1/2 inhibitor for the prevention of posterior capsule opacification: An in vitro study
por: Feng, Hao, et al.
Publicado: (2018)

Exosome Release Is Regulated by mTORC1
por: Zou, Wenchong, et al.
Publicado: (2018)

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
por: Du, Heng, et al.
Publicado: (2023)

The expression and significance of mTORC1 in diabetic retinopathy
por: Liu, Yanli, et al.
Publicado: (2020)

Glutaminolysis feeds mTORC1
por: Durán, Raúl V., et al.
Publicado: (2012)

Regulation of adiposity by mTORC1
por: Magdalon, Juliana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qne9qntdh4j89a6fkrs8ilhhkt